B G Feagan

Summary

Publications

  1. ncbi A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators
    B G Feagan
    London Clinical Trials Research Group, The John P Robarts Research Institute, London, Ont, Canada
    N Engl J Med 342:1627-32. 2000
  2. ncbi Transfusion practice in elective orthopaedic surgery
    B G Feagan
    London Clinical Trials Research Group, The John P Robarts Research Institute, London, Ontario, Canada
    Transfus Med 11:87-95. 2001
  3. ncbi Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics
    B G Feagan
    London Clinical Trials Research Group, London, Canada
    Can J Clin Pharmacol 8:188-98. 2001
  4. ncbi What do I do in my practice that isn't evidence based?
    Brian G Feagan
    Department of Medicine, University Hospital London Health Science Center, London, Ontario, Canada
    Inflamm Bowel Dis 8:422-5; discussion 426-7. 2002
  5. ncbi The efficacy, safety and acceptance of autologous blood donation as a blood conservation strategy
    Brian G Feagan
    The University of Western Ontario, London, Ontario, Canada
    Vox Sang 83:11-2. 2002
  6. doi Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab
    B G Feagan
    Department of Medicine, Robarts Research Institute, University of Western Ontario, London, Canada
    Aliment Pharmacol Ther 33:541-50. 2011
  7. ncbi CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial
    B G Feagan
    University of Western Ontario, London, ON, Canada
    Aliment Pharmacol Ther 23:617-28. 2006
  8. doi Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol
    B G Feagan
    Robarts Research Institute, University of Western Ontario, 100 Perth Drive, London, ON, Canada
    Aliment Pharmacol Ther 33:1143-51. 2011
  9. ncbi A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease
    B G Feagan
    The John P Robarts Research Institute, University of Western Ontario, London, ON, Canada
    Aliment Pharmacol Ther 21:373-84. 2005
  10. doi Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
    R Khanna
    Robarts Clinical Trials Inc, Robarts Research Institute, Western University, London, ON, Canada
    Aliment Pharmacol Ther 38:447-59. 2013

Collaborators

Detail Information

Publications15

  1. ncbi A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators
    B G Feagan
    London Clinical Trials Research Group, The John P Robarts Research Institute, London, Ont, Canada
    N Engl J Med 342:1627-32. 2000
    ..Better treatments are needed for the maintenance of remission. Although methotrexate is an effective short-term treatment for Crohn's disease, its role in maintaining remissions is not known...
  2. ncbi Transfusion practice in elective orthopaedic surgery
    B G Feagan
    London Clinical Trials Research Group, The John P Robarts Research Institute, London, Ontario, Canada
    Transfus Med 11:87-95. 2001
    ..If allogeneic transfusion rates are to be reduced, eligible patients should be encouraged to participate in ABD programmes. For patients who are ineligible, other preventative strategies should be introduced...
  3. ncbi Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics
    B G Feagan
    London Clinical Trials Research Group, London, Canada
    Can J Clin Pharmacol 8:188-98. 2001
    ..Infliximab is recommended for the treatment of active Crohn's disease refractory to conventional drugs, and is the treatment of choice for fistulizing Crohn's disease...
  4. ncbi What do I do in my practice that isn't evidence based?
    Brian G Feagan
    Department of Medicine, University Hospital London Health Science Center, London, Ontario, Canada
    Inflamm Bowel Dis 8:422-5; discussion 426-7. 2002
  5. ncbi The efficacy, safety and acceptance of autologous blood donation as a blood conservation strategy
    Brian G Feagan
    The University of Western Ontario, London, Ontario, Canada
    Vox Sang 83:11-2. 2002
  6. doi Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab
    B G Feagan
    Department of Medicine, Robarts Research Institute, University of Western Ontario, London, Canada
    Aliment Pharmacol Ther 33:541-50. 2011
    ..Certolizumab pegol, administered either every 2 weeks (q2w) or q4w, maintains efficacy in patients previously failing on the anti-TNF agent infliximab (WELCOME study)...
  7. ncbi CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial
    B G Feagan
    University of Western Ontario, London, ON, Canada
    Aliment Pharmacol Ther 23:617-28. 2006
    ..More than 50% of patients with Crohn's disease become either steroid resistant or dependent. Accordingly, development of new treatments for steroid-dependent Crohn's disease is a research priority...
  8. doi Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol
    B G Feagan
    Robarts Research Institute, University of Western Ontario, 100 Perth Drive, London, ON, Canada
    Aliment Pharmacol Ther 33:1143-51. 2011
    ..Patient-reported outcomes provide unique perspectives on the impact of chronic disease. It is unknown whether a combination of different instruments might improve sensitivity to clinically relevant changes in health status...
  9. ncbi A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease
    B G Feagan
    The John P Robarts Research Institute, University of Western Ontario, London, ON, Canada
    Aliment Pharmacol Ther 21:373-84. 2005
    ..To evaluate CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for the treatment of corticosteroid-dependent Crohn's disease...
  10. doi Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
    R Khanna
    Robarts Clinical Trials Inc, Robarts Research Institute, Western University, London, ON, Canada
    Aliment Pharmacol Ther 38:447-59. 2013
    ..Tumour necrosis factor (TNF)-antagonists have an established role in the treatment of inflammatory bowel diseases (IBDs), however, subtherapeutic drug levels and the formation of anti-drug antibodies (ADAs) may decrease their efficacy...
  11. doi Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study
    B G Feagan
    Robarts Research Institute, The University of Western Ontario, London, ON, Canada
    Aliment Pharmacol Ther 31:1276-85. 2010
    ..The effect of certolizumab pegol on employment status and work productivity has not been previously assessed...
  12. ncbi A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin
    B G Feagan
    University of Western Ontario, Robarts Research Institute, London, Canada
    Pharmacotherapy 21:89S-94S. 2001
    ..However, use of the clinical pathway was associated with a 1.7-day reduction in BDPM and fewer admissions of low-risk patients...
  13. ncbi A cluster-randomized controlled trial of a blood conservation algorithm in patients undergoing total hip joint arthroplasty
    Cindy J Wong
    Robarts Research Institute, Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada
    Transfusion 47:832-41. 2007
    ..The optimum strategy for reducing allogeneic blood transfusion in patients undergoing total hip joint arthroplasty (THJA) is unknown...
  14. pmc Transfusion practices for elective orthopedic surgery
    Brian G Feagan
    Department of Epidemiology and Biostatistics, London Clinical Trials Research Group, John P Robarts Research Institute, Ont
    CMAJ 166:310-4. 2002
    ..We examined the transfusion practice and blood conservation strategies for elective orthopedic procedures in 19 Canadian hospitals...
  15. ncbi A review of activity indices and end points for clinical trials in children with Crohn's disease
    Anne M Griffiths
    Hospital for Sick Children, Toronto, Ontario, Canada
    Inflamm Bowel Dis 11:185-96. 2005
    ....